STOCK TITAN

Alkermes Plc - ALKS STOCK NEWS

Welcome to our dedicated page for Alkermes Plc news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes Plc stock.

Overview

Alkermes plc (ALKS) is a global biopharmaceutical company that specializes in the development of innovative medicines for central nervous system disorders. With a robust portfolio and an expansive clinical pipeline, the company has established itself by addressing significant unmet medical needs in areas including schizophrenia, bipolar I disorder, addiction, and narcolepsy. Leveraging advanced biotechnology and proprietary technologies, Alkermes works at the intersection of scientific innovation and patient care, ensuring that its comprehensive strategy is grounded in deep technical expertise and quality research.

Core Business & Value Proposition

At its core, Alkermes is dedicated to advancing therapeutic solutions for complex CNS conditions. Its business model is fully integrated, spanning from early-stage research to commercial manufacturing and global distribution. The company’s approach centers on a dual strategy: it drives revenue through its commercial product portfolio while actively expanding a pipeline of clinical and preclinical candidates. This unique integration of research and commercial activities not only accelerates time-to-market for breakthrough therapies but also secures a competitive edge in a highly specialized field.

Research, Development, and Innovation

Alkermes invests substantially in research and development, channeling expertise towards understanding disease mechanisms and translating scientific insights into effective therapies. Its R&D endeavors are supported by state-of-the-art laboratories and partnerships with academic institutions globally. The company demonstrates a commitment to scientific excellence by engaging in rigorous clinical trials, exploring innovative pharmacological approaches, and pursuing novel targets such as the orexin 2 receptor. This focus on innovative drug development underscores its mission to deliver medicines that improve quality of life for patients with chronic disorders.

Commercial Products and Pipeline

One of the hallmarks of Alkermes is its diversified commercial product portfolio. The company commercializes proprietary medicines targeting psychiatric disorders like schizophrenia and bipolar I disorder through products that harmonize efficacy and safety. In parallel, it is at the forefront of developing investigational therapies for sleep disorders, particularly narcolepsy, using selective orexin 2 receptor agonists. Each product candidate is developed following stringent clinical standards, and the company consistently shares data at prestigious scientific conferences to enhance transparency and demonstrate its commitment to robust scientific validation.

Manufacturing and Global Presence

With headquarters in Dublin, Ireland, and operational centers in Massachusetts and Ohio, Alkermes has a well-integrated global infrastructure. Its manufacturing facilities and R&D centers are strategically located to optimize the flow of innovation from laboratory to patient. This geographical diversity not only reinforces its operational resilience but also provides access to substantial technological and regulatory expertise across regions.

Competitive Landscape and Industry Position

Operating in a competitive biopharmaceutical landscape, Alkermes differentiates itself through its integrated approach to drug development and commercialization. In contrast to companies that focus solely on early-stage research or late-stage commercialization, Alkermes strategically balances both, ensuring that innovations are rapidly translated into accessible therapies. The company’s rigorous clinical testing, commitment to quality, and deep knowledge of CNS disorders reaffirm its position as a trusted entity among healthcare providers and investors alike. Its transparent communication of clinical outcomes and ongoing research fosters expert-level credibility and differentiates it from competitors.

Commitment to Clinical Excellence and Scientific Rigor

Alkermes exemplifies a commitment to E-E-A-T principles (Experience, Expertise, Authoritativeness, and Trustworthiness) by maintaining high standards in clinical research and continuously publishing peer-reviewed data. Its participation in international conferences and scientific symposiums contributes to a global discourse on psychiatric and neurological treatments. The company's methodical approach to drug development is reflected in its data-driven decision making and consistent presentation of safety and efficacy results.

Operational Strategy and Market Impact

The integrated model of Alkermes facilitates operational agility and sustained innovation. By leveraging its global manufacturing capabilities and cross-functional expertise, the company rapidly adapts to changes within the therapeutic landscape. Its dual revenue streams—from commercial products and advanced R&D initiatives—highlight a balanced portfolio that caters to current market demands while positioning the company to explore emerging opportunities in neuroscience. The clear strategic focus on high-priority indications offers a comprehensive framework that aligns clinical advancements with market realities.

Collaborations and Industry Engagement

Alkermes actively collaborates with academia, research institutions, and clinical networks, fostering an environment of shared knowledge and innovation. Through structured partnerships, the company gains access to cutting-edge research and enhances its ability to address complex clinical challenges, thereby reinforcing its industry standing and driving advancements in therapeutic areas with significant unmet needs.

Conclusion

In summary, Alkermes plc is a paradigm of innovation and integration in the biopharmaceutical industry. Its relentless pursuit of scientific advancement in CNS disorders, combined with a diversified portfolio and a strategy rooted in operational excellence, positions it as a trusted and authoritative source within the field. With an unwavering commitment to rigorous clinical research and a well-calibrated commercial strategy, Alkermes continues to set benchmarks in the global effort to improve patient outcomes in mental health and neurological disorders.

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on April 9, 2025. The company's management will join a webcast panel discussion titled 'Development of Orexin Receptor Agonist in Sleep-Wake Disorders' at 11:45 a.m. EDT.

The global biopharmaceutical company, focused on neuroscience innovations, maintains a portfolio of commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Their pipeline includes clinical and preclinical candidates for neurological disorders, specifically narcolepsy and idiopathic hypersomnia.

The company operates from its headquarters in Ireland, with additional facilities including a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. The panel discussion webcast will be accessible through the Investors section of Alkermes' website and remain archived for 14 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Alkermes (ALKS) has launched Vibrance-3, a Phase 2 clinical study evaluating ALKS 2680 for idiopathic hypersomnia (IH). The study will assess the safety and efficacy of their novel oral selective orexin 2 receptor agonist versus placebo in adults with IH.

The randomized, double-blind trial will enroll approximately 96 patients across U.S., Australia, and Europe sites. Participants will receive one of three doses (10mg, 14mg, or 18mg) or placebo once-daily for eight weeks. The primary endpoint measures decrease in sleepiness using the Epworth Sleepiness Scale score.

This development follows encouraging Phase 1b data and addresses a significant unmet need, as over 90% of patients in a recent Sleep Consortium survey reported moderate to high impact of IH symptoms on their lives. IH affects an estimated 40,000 people in America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
-
Rhea-AI Summary

A new national survey conducted by The Harris Poll for Alkermes (ALKS) reveals critical insights into healthcare providers' perspectives on treating schizophrenia and bipolar I disorder (BDI). The September 2024 survey, involving over 250 healthcare providers, highlights that 98% of respondents consider patient quality of life equally important as symptom management.

Key findings show that medication adherence is a primary concern, with patients switching medications frequently - BDI patients average seven switches and schizophrenia patients eight switches in their lifetime. About 66% of providers reported good/excellent quality of life for BDI patients, compared to only 21% for schizophrenia patients.

The survey revealed that providers prioritize symptom management (98% for BDI, 97% for schizophrenia) and quality of life improvements (96% for BDI, 94% for schizophrenia) when considering treatment efficacy. Common treatment challenges include medication effectiveness (82%) and side effects (81%). Most providers (97%) seek options to minimize the number of different treatments patients need to take.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two major upcoming investor conferences in March 2025. The company will engage in webcast fireside chats at the TD Cowen 45th Annual Health Care Conference on March 5 at 9:50 a.m. ET and the Leerink Partners Global Healthcare Conference 2025 on March 12 at 11:20 a.m. ET.

The webcasts will be accessible through the Investors tab on Alkermes' website and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with a portfolio including treatments for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations across Ireland, Massachusetts, and Ohio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.17%
Tags
conferences
-
Rhea-AI Summary

Alkermes (ALKS) reported strong financial results for Q4 and full-year 2024, with total revenues of $1.56 billion. The company achieved 18% year-over-year growth in proprietary product net sales, reaching over $1 billion. Key highlights include:

- GAAP Net Income from continuing operations of $372.1 million ($2.20 per share)
- Total proprietary net sales reached $1.08 billion
- Year-end cash position of $824.8 million
- Company became debt-free after retiring $290 million in debt

For 2025, Alkermes provided financial guidance including:
- Total revenue expectations of $1.34-1.43 billion
- GAAP Net Income of $175-205 million
- EBITDA guidance of $215-245 million

The company is advancing its neuroscience pipeline, with ALKS 2680 Phase 2 studies in narcolepsy ongoing and data expected in H2 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.82%
Tags
-
Rhea-AI Summary

Alkermes (ALKS) has announced it will host a conference call and webcast on February 12, 2025, at 8:00 a.m. ET to discuss its fourth quarter and year-end 2024 financial results. During the presentation, management will also outline financial expectations for 2025 and provide a company update.

The event will be accessible through the company's website investor section, with a conference call available at +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international participants. A replay will be available approximately two hours after the event.

Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products targeting alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
conferences earnings
Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Richard Pops will deliver a corporate overview and update on Wednesday, Jan. 15, 2025, at 11:15 a.m. PST, followed by a Q&A session. The presentation will be accessible via webcast on the company's website under the Investors tab and will remain archived for 14 days.

Alkermes is a global biopharmaceutical company focused on neuroscience innovation. Their portfolio includes commercial products treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company's pipeline features clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia. Based in Ireland, Alkermes maintains a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two major investor conferences in December 2024. The company will present at the 7th Annual Evercore ISI HealthCONx Conference on December 3 at 10:25 a.m. ET and the Piper Sandler 36th Annual Healthcare Conference on December 4 at 4:00 p.m. ET.

The presentations will be accessible via live webcasts on the company's website under the Investors tab and will remain archived for 14 days. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
conferences
-
Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) has announced its participation in two upcoming investor conferences in November 2024. The company will present at the Stifel Healthcare Conference on November 18 at 8:35 a.m. ET and the Jefferies London Healthcare Conference on November 19 at 8:00 a.m. ET. Live webcasts will be available on Alkermes' website under the Investors tab and archived for 14 days.

Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company maintains operations in Ireland, Massachusetts, and Ohio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
conferences
Rhea-AI Summary

Alkermes announced presentations at two key scientific conferences, showcasing research on LYBALVI® (olanzapine and samidorphan), ARISTADA® (aripiprazole lauroxil), and ALKS 2680. At the 37th Annual Psych Congress and the 2024 Neuroscience Education Institute Congress, Alkermes presented 12 posters, including a study on healthcare resource utilization in patients with schizophrenia and bipolar I disorder after LYBALVI initiation. The study revealed significant reductions in inpatient admissions and emergency department visits. Limitations include potential data omissions and coding errors. Additionally, safety and efficacy data from a phase 1b study of ALKS 2680 in narcolepsy were presented.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
none

FAQ

What is the current stock price of Alkermes Plc (ALKS)?

The current stock price of Alkermes Plc (ALKS) is $32.65 as of April 2, 2025.

What is the market cap of Alkermes Plc (ALKS)?

The market cap of Alkermes Plc (ALKS) is approximately 5.2B.

What is the core focus of Alkermes plc?

Alkermes plc is focused on developing innovative medicines for central nervous system disorders, including schizophrenia, bipolar I disorder, addiction, and narcolepsy. The company integrates research, development, and commercialization to address significant unmet medical needs.

How does Alkermes generate its revenue?

The company generates revenue through its diversified portfolio of proprietary commercial products as well as through an extensive clinical pipeline of investigational therapies. Its integrated approach allows for both immediate market impact and long-term growth through innovative drug development.

What therapeutic areas does Alkermes specialize in?

Alkermes specializes in various CNS disorders such as schizophrenia, bipolar I disorder, and substance dependence, along with investigational treatments for sleep disorders like narcolepsy. Its focus remains on conditions with significant unmet needs in neurology and psychiatry.

Where are Alkermes' key operational facilities located?

Headquartered in Dublin, Ireland, Alkermes has critical R&D and corporate operations in Massachusetts as well as manufacturing facilities in Ireland and Ohio. This global footprint supports its integrated model of research and commercialization.

How does Alkermes maintain its competitive edge?

By combining rigorous clinical research with an integrated business model, Alkermes stays ahead in the competitive biopharmaceutical space. Its ongoing innovations, commitment to publishing data, and global manufacturing capabilities differentiate it within the CNS treatment landscape.

What is unique about Alkermes' research and development strategy?

Alkermes’ R&D strategy is marked by its focus on innovation and scientific rigor. The company invests in cutting-edge research, utilizes proprietary technologies, and maintains strategic partnerships, which together drive the development of next-generation therapies for CNS disorders.

Can you describe the company’s approach to clinical trials?

Alkermes conducts well-structured clinical trials with a focus on safety, efficacy, and long-term clinical outcomes. The company frequently presents its data at international scientific meetings and employs rigorous protocols to validate its therapeutic candidates.

How does Alkermes demonstrate expertise and trustworthiness?

Through a long history of scientific innovation, transparent data sharing, and a comprehensive approach to drug development, Alkermes exemplifies the E-E-A-T principles. Its consistent clinical performance and emphasis on peer-reviewed research help establish its authority in the CNS therapeutic space.
Alkermes Plc

Nasdaq:ALKS

ALKS Rankings

ALKS Stock Data

5.21B
159.29M
1.45%
106.03%
8.61%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 4